Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE.

Remme WJ.

Cardiovasc Drugs Ther. 2007 Dec;21(6):405-7. No abstract available.

PMID:
17994273
2.

Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.

Ferrari R, Fox K.

Drugs. 2009;69(3):265-77. doi: 10.2165/00003495-200969030-00003. Review.

PMID:
19275271
3.

Inhibition of the renin-angiotensin system for lowering coronary artery disease risk.

Sheppard RJ, Schiffrin EL.

Curr Opin Pharmacol. 2013 Apr;13(2):274-9. doi: 10.1016/j.coph.2013.03.001. Epub 2013 Mar 21. Review.

PMID:
23523606
5.

Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.

Ferrari R, Guardigli G, Ceconi C.

Cardiovasc Drugs Ther. 2010 Aug;24(4):331-9. doi: 10.1007/s10557-010-6244-x. Review.

PMID:
20577898
7.

Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies.

Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R.

Cardiovasc Drugs Ther. 2007 Dec;21(6):423-9. Epub 2007 Nov 15.

PMID:
18004652
9.

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.

Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D, Ferrari R; EUROPA Investigators; PERTINENT Investigators and the Statistical Committee.

Cardiovasc Res. 2007 Jan 1;73(1):237-46. Epub 2006 Nov 10.

PMID:
17140552
10.

Kinin- and angiotensin-converting enzyme (ACE) inhibitor-mediated nitric oxide production in endothelial cells.

Skidgel RA, Stanisavljevic S, Erdös EG.

Biol Chem. 2006 Feb;387(2):159-65. Review.

PMID:
16497147
11.
12.

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.

Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators.

Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10.

PMID:
19082699
13.

Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.

Brugts JJ, Boersma E, Simoons ML.

Pharmacogenomics. 2010 Aug;11(8):1115-26. doi: 10.2217/pgs.10.103. Review.

PMID:
20712529
14.

The landscape after PEACE: do all ACE inhibitors act in an identical way?

Grajek S.

Curr Med Res Opin. 2006 Feb;22(2):265-74.

PMID:
16466598
15.
16.

Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy.

Morawietz H, Rohrbach S, Rueckschloss U, Schellenberger E, Hakim K, Zerkowski HR, Kojda G, Darmer D, Holtz J.

Eur J Clin Invest. 2006 Oct;36(10):705-12.

PMID:
16968466
17.
18.
19.

Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.

Donnelly R, Manning G.

J Renin Angiotensin Aldosterone Syst. 2007 Mar;8(1):13-22. Review.

PMID:
17487822

Supplemental Content

Support Center